Expression of RGS2, but not other RGS proteins, abolished androgen-independent AR activity in androgenindependent LNCaP cells and CWR22Rv1 cells. In LNCaP cells, RGS2 inhibited G q -coupled GPCR signaling. Expression of exogenous wild-type RGS2, but not its GAP-deficient mutant, significantly reduced AR activation by constitutively activated G q Q209L mutant whereas silencing endogenous RGS2 by siRNA enhanced G q Q209L-stimulated AR activity. RGS2 had no effect on RGS-insensitive G q Q209L/G188S-induced AR activation. Furthermore, extracellular signal-regulated kinase 1/2 (ERK1/2) was found to be involved in RGS2-mediated regulation of androgen-independent AR activity. In addition, RGS2 functioned as a growth suppressor for androgen-independent LNCaP cells whereas androgensensitive LNCaP cells with RGS2 silencing had a growth advantage under steroid-reduced conditions. Finally, RGS2 expression level was significantly decreased in human prostate tumor specimens. Taken together, our results suggest RGS2 as a novel regulator of AR signaling and its repression may be an important step during prostate tumorigenesis and progression.
Introduction
Prostate cancer is the most commonly diagnosed cancer in American men and the second leading cause (after lung) of cancer mortality (Jemal et al., 2005) . In early stages, the growth of prostate cancer cells depends on androgens, thus hormone therapies that remove androgen and block androgen receptor (AR) cause the repression of prostate tumors. Unfortunately, the majority of prostate cancers eventually progress from being androgen-dependent to androgen-independent, making hormone therapies ineffective (Feldman and Feldman, 2001) . Despite decades of intense laboratory and clinical investigations, the treatment for androgenindependent prostate cancer is still limited. The precise mechanisms underlying prostate cancer progression have remained largely unknown. It cannot be simply ascribed to the loss of AR expression since most of these prostate tumors still express the functional AR (Sadi et al., 1991; Chodak et al., 1992; Hobisch et al., 1996) . Thus, at least some hormone-refractory prostate cancers are thought to be caused by ligand-independent activation of AR (Heinlein and Chang, 2004) . For example, in most androgen-independent prostate tumors, AR is activated despite the continued presence of hormonal therapies and is involved in the transition of prostate cancer from androgen dependence to androgen independence (Grossmann et al., 2001) . Additionally, most hormone-refractory prostate tumor cells express PSA, an androgen-regulated antigen, implying the functional activity of AR in these carcinomas (Taplin and Balk, 2004) . Therefore, understanding the mechanisms of signal pathways regulating AR activation is critical for overcoming the current therapeutic limitations treating this disease. Recent works have suggested that signaling pathways triggered by G protein-coupled receptors (GPCRs) can induce androgen-independent AR activation, thus sustaining androgen-independent cell growth of prostate cancer (reviewed by Daaka, 2004) .
The basic signaling unit of a GPCR signaling system contains four major components: receptor, G protein (trimeric abg), effector and regulators of G-protein signaling (RGS) protein (Ross and Wilkie, 2000) . G proteins, classified into G s , G i , G q and G 12 subfamilies, stimulate intracellular signal proteins (effectors) when they bind GTP in response to ligand-activated GPCRs; signaling ends when bound GTP is hydrolysed. RGS proteins display GTPase activating protein (GAP) activity toward G proteins. They increase the rate of GTP hydrolysis of G proteins as many as 1000-fold, thus inactivating G-protein activity. Therefore, the intensity and duration of a GPCR signaling are controlled at least in part by GPCR-mediated activation of G proteins and RGS-mediated inactivation of G proteins.
Basic and clinical research results demonstrate that GPCR systems in some advanced prostate cancers may be excessively activated, due to abnormally elevated ligands of GPCRs (Nelson et al., 1996; Porter and BenJosef, 2001; Xie et al., 2002) and/or overexpression of GPCRs including endothelin A receptor (Gohji et al., 2001) , bradykinin 1 receptor (Taub et al., 2003) , folliclestimulating hormone receptor (Ben-Josef et al., 1999) , thrombin receptor (Chay et al., 2002) and the orphan prostate-specific GPCR (Xu et al., 2000; Xia et al., 2001; Weng et al., 2005) . In addition, advanced prostate cancers often have increased numbers of neuroendocrine cells that are known to secrete neuropeptides (Abrahamsson, 1999) . These neuropeptides, exemplified by bombesin and neurotensin, acting through their GPCRs result in androgen-independent AR activation, thus promote prostate cancer cells from an androgendependent to androgen-independent state (Lee et al., 2001; Dai et al., 2002) .
Since RGS proteins inhibit GPCR signaling in cells, it is reasonable to hypothesize that dysregulated RGS proteins can contribute to the aberrant GPCR signaling observed in advanced prostate cancers. Therefore, inhibiting aberrant GPCR signaling by targeting RGS gene expression in prostate cancer cells may help control prostate cancer development and/or progression. Currently, about 20 different mammalian RGS proteins that share a conservative RGS domain have been identified and classified into R4, R7, R12, RZ and RL subfamilies (Ross and Wilkie, 2000; Hollinger and Hepler, 2002) . Of all the modulators involved in GPCR signaling, RGS proteins are the only ones showing dynamic changes of gene expression in response to various stimuli (Ingi et al., 1998; Burchett et al., 1999; Robinet et al., 2001; Grillet et al., 2003) and have been shown to be biologically important in neuronal, cardiovascular, and lymphocytic activities (Hollinger and Hepler, 2002; Neubig and Siderovski, 2002; Wieland and Mittmann, 2003) . However, the role of RGS proteins in prostate carcinogenesis has not been explored in any depth.
The LNCaP cell line, originally established from a human prostate adenocarcinoma, is androgen sensitive and moderately differentiated. It has been used to study the regulation of AR signaling by GPCR signaling pathways. In vitro, stimulation of the endogenous G q -coupled bombesin/gastrin-releasing peptide (GRP) receptor (Lee et al., 2001 ) or the G s -coupled b 2 -adrenergic receptor (Kasbohm et al., 2005) activates AR in LNCaP cells. In addition, the neuropeptide calcitonin, activating both G s and G q signaling pathways, can stimulate androgen-independent growth of LNCaP cells (Shah et al., 1994) . Recently, Lin and his co-workers developed a useful prostate cancer cell model including sublines of LNCaP cells (Lin et al., 1998; Igawa et al., 2002) . The sublines express the similar level of functional AR. However, the lowpassage LNCaP cells (C33) grow slowly in an androgen-sensitive manner, whereas high-passage (C81) cells grow aggressively and also become androgen-independent even though they are still androgen-responsive. This tumor cell model closely resembles the two stages of tumorigenesis with the acquisition of hormonerefractiveness as seen in prostate cancer patients (Karan et al., 2001 Denmeade et al., 2003) and is useful in studying the progressive changes in the primary and metastatic stages of prostate cancer (Karan et al., 2001; Lee et al., 2003; Lin et al., 2003; Unni et al., 2004) .
Here we provide data showing that selective reduction of a specific type of RGS proteins, RGS2, is associated with acquisition of androgen-independence by prostate cancer cells. RGS2 is a 24-kDa protein and was originally identified as an early response gene named as GOS8 (G0/G1 switch regulatory gene 8) that was upregulated during the activation of T cells (Siderovski et al., 1994; Wu et al., 1995) . Subsequent studies indicated that it has an RGS domain and can profoundly inhibit G q -coupled GPCR signaling in vivo, and therefore was renamed as RGS2 (Druey et al., 1996) . RGS2 also functions as a GAP for G i (Ingi et al., 1998; Hains et al., 2004) and may produce inhibitory effects on G s -mediated adenylate cyclase activity via binding to adenylate cyclase (Sinnarajah et al., 2001; Salim et al., 2003) . Functions of RGS2 in the immune, neurological and cardiovascular systems are well established utilizing RGS2-deficient mice (Oliveira-Dos- Santos et al., 2000; Heximer et al., 2003; Tang et al., 2003) . A recent study suggests that RGS2 appears to be a locus implicated in solid tumor development (Collier et al., 2005) . Interestingly, RGS2 maps to human chromosome 1q31 (Wu et al., 1995) , a region where 20-40% of allelic loss was found in clinical human prostate tumor specimens (Cunningham et al., 1996; Karan et al., 2001) . Using a quantitative real-time PCR technique, we found that the expression level of RGS2 is significantly downregulated in human prostate tumor specimens as compared to normal prostate tissues. Expression of the wild-type RGS2 but not GAP-deficient RGS2 mutant blocks G q -induced activation of AR in LNCaP-C33 and LNCaP-C81 cells. Moreover, our results demonstrated that RGS2 can inhibit both the constitutively activated extracellular signal-regulated kinases (ERKs) and androgen-independent AR activity in androgenindependent prostate cancer cells, thus blocking the androgen-independent prostate cancer cell growth.
Results
Androgen-independent AR activity in androgenindependent LNCaP-C81 cells To characterize the AR activity in LNCaP cells before and after acquisition of androgen-independence, we transiently transfected LNCaP cells with an RGS2 inhibits androgen receptor X Cao et al AR-regulated luciferase reporter gene (ARE 3 -tk-LUC) to detect AR-mediated gene transcription. The transfected cells were cultured in a steroid-reduced medium without or with synthetic androgen R1881. As shown in Figure 1a , in the absence of exogenous androgen, the basal relative luciferase activity in androgen-independent LNCaP-C81 cells was about seven-fold higher than that in androgen-sensitive LNCaP-C33 cells (Po0.01).
At the optimal concentration of R1881 (5 nM) (Sato et al., 1997) , additional activation of AR was observed (three-fold in LNCaP-C81 cells vs 16-fold in LNCaP-C33 cells). Prostate-specific antigen (PSA) is an AR-regulated serine protease, secreted by the prostate. The elevated level of PSA in circulation is known as the most sensitive and reliable marker for diagnosing and monitoring the relapse of prostate cancer after hormone therapies (Candas et al., 2000) . Thus, we performed Western blot analysis to examine PSA secretion from equal number of LNCaP cells using an anti-PSA antibody. Similar to previous report (Igawa et al., 2002) , in the steroidreduced medium, the level of secreted PSA from androgen-independent LNCaP-C81 cells was about six-fold higher than that from androgen-sensitive LNCaP-C33 cells (Figure 1b, Po0.01) . Moreover, the degree of 5 nM R1881 stimulation of PSA secretion from LNCaP-C33 cells was much higher than that from LNCaP-C81 cells (12-fold vs 1.6-fold). Thus, our results strongly suggest that AR in LNCaP-C81 cells is already activated under steroid-reduced medium although androgen R1881 can still induce additional modest activation of AR, as seen in hormone-refractory clinical prostate cancers (Taplin and Balk, 2004) .
Downregulation of RGS2 in androgen-independent prostate cancer cells
To address the role of RGS proteins in the regulation of androgen-responsiveness in prostate cancer cells, we performed quantitative real-time PCR to compare the mRNA expression levels of 14 RGS genes between androgen-sensitive LNCaP-C33 and androgen-independent LNCaP-C81 cells using the primer sets for human RGS genes (Table 1) . These RGS genes were selected to represent five subgroups of the mammalian RGS gene family (Ross and Wilkie, 2000; Hollinger and Hepler, 2002) . The housekeeping gene b-Actin was used as the normalizing gene in our experiments. While the transcripts of two RGS genes (RGS 7 and 20) were undetectable in either LNCaP-C33 or LNCaP-C81 cells, there was only a moderate difference (0.8-to 2.3-fold) in the mRNA levels of most RGS genes tested between these two sublines of LNCaP cells. However, the expression of RGS2 was decreased by more than 30-fold in LNCaP-C81 cells, compared to LNCaP-C33 cells (Figure 2a ). Similar results were obtained when another housekeeping gene cyclophilin B was used as the normalizing gene (data not shown). Consistent with this result, the conventional PCR product of RGS2 was clearly detected in LNCaP-C33 cells but not in LNCaP-C81 cells (Figure 2a, inset) . In support of this finding, the endogenous RGS2 protein was detected in androgen-sensitive LNCaP-C33 cells but not in androgenindependent LNCaP-C81 cells by Western blot assay while these LNCaP-C81 cells were capable of expressing exogenous RGS2 (Figure 2b ). Interestingly, Western blot assays also showed that RGS2 protein could not be detected in another androgen-independent prostate cancer CWR22Rv1 cell line that was derived from a relapsed xenograft tumor and possesses features of clinically advanced disease such as AR expression and androgen-independent proliferation (Sramkoski et al., 1999) . The expression levels of AR are similar between LNCaP-C33 and LNCaP-C81 cells (Igawa et al., 2002; Figure 2b ). In contrast, the full-length AR from CWR22Rv1 cell lysates displays a consistently slower mobility compared to LNCaP cells and a prominent, truncated AR mutant with deletion of the ligand Figure 1 Androgen-independent AR activity in LNCaP cells. (a) Dual reporter genes (ARE 3 -tk-LUC and pRL-tk) were transfected into LNCaP-C33 and LNCaP-C81 cells. Cells were cultured in steroid-reduced medium without or with R1881 (5 nM) treatment for 24 h. Luciferase activities of cell lysates were measured using the dual luciferase assay system (Promega). Bars show the mean7s.e. of the normalized luciferase activities relative to LNCaP-C33 cells in the absence of R1881 (n ¼ 5) (RLUs, relative luciferase units). (b) The PSA secretion was analysed by Western blotting using the anti-PSA antibody (inset is representative of four experiments). Each lane contained 50 ml of 1% charcoal-stripped FBS conditioned medium from LNCaP cells cultured without or with 5 nM R1881 for 48 h. Data show the mean7s.e. of relative PSA secretion normalized to cell numbers. *Po 0.01 compared to LNCaP-C33 cells in the absence of R1881.
RGS2 inhibits androgen receptor X Cao et al binding domain was also detected, consistent with the previous report (Tepper et al., 2002) . Thus, our results suggest that RGS2 was selectively silenced in ARpositive prostate cancer cells after acquisition of androgen-independence.
RGS2 inhibits the androgen-independent AR activity in androgen-independent prostate cancer cells To investigate whether dysregulation of RGS2 is involved in the loss of androgen dependence of prostate cancer cells, we examined the effects of exogenously expressed hemagglutinin (HA)-tagged RGS proteins on the AR activity in LNCaP cells. Western blot assays using a monoclonal anti-HA antibody showed similar expression levels of these RGS proteins in LNCaP-C81 cells (Figure 3a, inset) . However, expression of RGS2, but not RGS5 or RGS10, decreased the basal ARregulated luciferase activity in androgen-independent LNCaP-C81 cells. RGS2 reduced androgen-independent AR activity by more than 80% (Po0.01); while RGS4 had only slight inhibitory effect (o30%). Similar results were observed when untagged RGS proteins were expressed in LNCaP-C81 cells (data not shown). Interestingly, neither the expression of AR (Figure 2b ) nor the androgen-stimulated AR activity (Figure 3a) was affected by the expression of RGS2 in LNCaP-C81 cells. Consistent with the reporter gene assays, expression of RGS2 in LNCaP-C81 cells reduced androgenindependent PSA secretion by 90% (Figure 3b , Po0.01). Interestingly, RGS4 also had an inhibitory effect about 50% (Po0.01) while the effect of RGS5 or RGS10 was statistically insignificant (P>0.05). In contrast, none of RGS proteins significantly impacted the basal or R1881-stimulated AR activity in androgensensitive LNCaP-C33 cells (data not shown).
We also tested another AR-positive, androgenindependent prostate cancer CWR22Rv1 cells. In the RGS2 inhibits androgen receptor X Cao et al absence of androgen, CWR22Rv1 cells were found to possess high basal AR activity as shown in reporter gene assays (Figure 3c ), which was increased about two-fold by 5 nM R1881 but significantly inhibited by exogenous RGS2 in a dose-dependent manner with the maximum inhibition of 50%. These experiments suggest that RGS2 can inhibit androgen-independent AR activation in androgen-independent prostate cancer cell lines. Since better transfection efficiency with greater inhibitory effect of RGS2 on the androgen-independent AR activity was observed in androgen-independent LNCaP cells compared to CWR22Rv1 cells, we focused our attention on LNCaP cells that provide a model system to study the biological importance of dysregulated RGS2 in androgen-independent activation of AR.
RGS2 inhibits constitutively activated G q Q209L mutant-induced AR activation
Data obtained from androgen-independent LNCaP-C81 and CWR22Rv1 prostate cancer cells suggest that RGS2 specifically inhibits the androgen-independent activation of AR. RGS2 can inhibit both G q -coupled and G i -coupled signaling pathways through its GAP activity (Druey et al., 1996; Ingi et al., 1998; Kammermeier and Ikeda, 1999; Hains et al., 2004) . We found that expression of constitutively activated G i1 Q204L mutant in LNCaP-C33 cells had no effect on the ARregulated luciferase activity (data not shown), consistent RGS2 inhibits androgen receptor X Cao et al with a previous report (Kasbohm et al., 2005) . Therefore, we further investigated whether the modulation of G q -coupled signaling by RGS2 would affect the AR activity in those cells. Expression of the constitutively activated G q Q209L mutant but not the wild-type G q induced a dosedependent increase in the AR-regulated luciferase activity in both LNCaP-C33 and LNCaP-C81 cells in the absence of androgen (Figure 4a ) using the ARE 3 -tk-LUC reporter construct. The maximal stimulation of about six-fold was achieved in androgen-sensitive LNCaP-C33 cells (bar 4 vs bar 1). Coexpression of RGS2 decreased G q Q209L-stimulated AR activity by more than 80% (bar 6 vs bar 4). As shown in Figure 4a (inset), expression of G q and/or RGS2 had no significant effect on the expression levels of AR in LNCaP-C33. Deletion of the ARE 3 from the ARE 3 -tk-LUC vector abolished the changes of transcription in response to the expression of constitutively activated G q Q209L or RGS2 (data not shown). In androgen-independent LNCaP-C81 cells, due to a high basal activity, maximal stimulation by G q Q209L was about two-fold (bar 10 vs bar 9). Co-transfection of RGS2 significantly reduced both the basal and G q Q209L-stimulated AR activity in LNCaP-C81 cells (bar 11 and 12). It should be noted that neither the expression level of AR protein nor the AR activity of LNCaP cells in the presence of androgen was affected by the expression of G q Q209L or RGS2 (data not shown).
To test the role of RGS2 GAP activity, we generated the mutation Asn 149 to Ala within the highly conserved RGS domain of RGS2. The corresponding mutation Asn 128 to Ala in RGS4 reduces its binding to G proteins by over three orders of magnitude (Posner et al., 1999) . We reconstituted M1 muscarinic receptors and G q (m1AchR-G q ) into proteoliposomes as described previously (Tu et al., 2001 ) and tested the GAP activity of wild-type RGS2 and RGS2N149A mutant in a steadystate, G q -coupled GTPase assay (Wang et al., 1998) . As shown in Figure 4b , RGS2N149A mutant retained less Figure 4 RGS2 inhibits androgen-independent, Gq-stimulated AR activity. LNCaP cells were cultured in steroid-reduced medium for 48 h and luciferase activities of cell lysates were measured. Each bar represents the mean7s.e. of the normalized luciferase activities (n ¼ 4) with *Po0.01 compared to cells transfected with pcDNA3.1 vector. (a) Cells were co-transfected with dual reporter genes (0.1 mg) and the wild-type G q or constitutively activated G q Q209L mutant plasmid, alone or together with HA-tagged RGS2 plasmid (1 mg). Inset: Expression levels of AR, G q and HAtagged RGS2 were examined by Western blot. LNCaP cells also express endogenous G q as shown in lane 1, 9 and 11. (b) Mutation of Asn 149 to Ala (N149A) in RGS2 abolished both its G q GAP activity and its ability to bind to constitutively activated G q . Carbachol-stimulated GTPase activity in m1AchR-G q vesicles was measured in the presence of the indicated concentrations of purified wide-type (WT) RGS2 () or RGS2N149A mutant ('). G q and m1AchR were 1.3 and 0.27 nM, respectively in assays. Inset: HEK293 cells were transfected with pcDNA3.1 encoding G q Q209L mutant. HEK293 cell extracts (50 mg) containing expressed G q Q209L protein (Load) were incubated without (CN) or with 20 nM purified His6-tagged RGS2 (WT) or N149A mutant. NTANi 2 þ agarose (Qiagen) was used to precipitate His6-tagged RGS2 (WT or N149A) and any associated proteins. Samples were analysed by SDS-PAGE and blotted with the G q antibody and RGS2 antibody. Purified G q (10 ng, lane 1) was used as a positive control. (c) LNCaP-C33 cells were cotransfected with dual reporter genes (0.1 mg), alone or together with 0.4 mg G q Q209L or G q Q209L/G188S plus 1 mg of vector, vector encoding HA-tagged wild-type RGS2 or its N149A mutant. Inset: Expression levels of HA-tagged RGS2 or its N149A mutant were examined by Western blot and b-Actin was used as loading controls. (d) The intracellular localization of C-terminal GFP-tagged RGS2 in LNCaP-C33 cells co-transfected with G q mutants as indicated. Confocal microscopic images shown are representative of at least 50 living cells.
RGS2 inhibits androgen receptor
X Cao et al than 1% of the GAP activity of wild-type protein, presumably due to the loss of binding to G q (Figure 4b , inset). As expected, RGS2N149A mutant lost its ability to inhibit the G q Q209L-stimulated AR activity in LNCaP-C33 cells in the absence of androgen (Figure 4c ) although its expression level was similar to the wild-type RGS2 (Figure 4c , Inset).
To further determine the contribution of RGS2 to the regulation of AR activity mediated by G q in prostate cancer cells, we used a RGS-insensitive G q mutant (Gly 188 to Ser) that abrogates the RGS-G protein interaction but does not affect other functions of the G protein such as coupling to receptors or effectors (DiBello et al., 1998) . We transfected G q Q209L (RGSsensitive) or G q Q209L/G188S double mutant (RGSinsensitive) into androgen-sensitive LNCaP-C33 cells. As shown in Figure 4c , co-transfection of RGS2 only blocked G q Q209L-stimulated AR activity but had no significant effect on G q Q209L/G188S-stimulated AR activity in the absence of androgen. Moreover, G q Q209L/G188S had stronger stimulatory effect on the androgen-independent AR activity than G q Q209L in LNCaP-C33 cells, although their expression levels were similar (data not shown).
We also examined the intracellular localization of GFP-tagged RGS2 to assess the importance of RGS2/ G q interaction in the regulation of AR activity. In the absence of exogenous G q , GFP-tagged RGS2 was localized predominantly in the nucleus of LNCaP-C33 cells (Figure 4d ). Constitutively activated G q Q209L caused significant amounts of GFP-RGS2 to be re-localized to the plasma membrane. In contrast, the RGSinsensitive G q Q209L/G188S mutant did not induce GFP-RGS2 association with the plasma membrane, consistent with previous findings in HEK293 cells (Roy et al., 2003) .
Silencing endogenous RGS2 by siRNAs enhances G q Q209L-induced AR activation in LNCaP-C33 cells To test the hypothesis that endogenous RGS2 is capable of downregulating androgen-independent activation of AR, we designed and synthesized a panel of gene-specific siRNAs targeting human RGS2 gene. One siRNA (RGS2si-3, targeting RGS2 sequence: 5 0 -AAAGCCACAAATCACCACAGA-3 0 , not homogenous to other RGS genes) effectively suppressed the expression of endogenous RGS2 protein, but no RGS10 protein in LNCaP-C33 cells (Figure 5a ). In order to avoid the possibility of off-target effect of siRNAs (Jackson et al., 2003) , we also generated three psiRNAhH1zeo (G2) expression vectors that express siRNAs targeting the 3 0 -untranslated region (3 0 -UTR) of human RGS2 gene. One RGS2 siRNA expression vector (RGS2si-5, targeting RGS2 3 0 -UTR sequence: 5 0 -GGAAACATCACTCAGAACTAT-3 0 ) strongly downregulated RGS2 expression in LNCaP-C33 cells. The knockdown effect of RGS2si-3 or RGS2si-5 was apparently achieved by a sequence-specific event because their control siRNAs with scrambled sequences had no significant effect on the expression of RGS2 protein. Under steroid-reduced medium culture conditions, introduction of RGS2si-3 or RGS2si-5 expression vector into LNCaP-C33 cells resulted in an increased basal AR activity (lane 1 vs 4) and enhanced the AR activity induced by G q Q209L mutant by over three-fold (lane 2 vs 5) as demonstrated in an AR-regulated luciferase reporter assay (Figure 5b) . However, the AR activity in the presence of R1881 (5 nM) was not affected (lane 3 vs 6).
ERK1/2 mediate the inhibition of androgen-independent AR activity by RGS2 in LNCaP cells Since the mitogen-activated protein kinase (MAPK), particularly the ERK signaling pathway, plays an important role in prostate cancer progression (Gioeli et al., 1999; Bakin et al., 2003) and ERK1/2 are constitutively activated in high-passage androgenindependent LNCaP cells (Lee et al., 2003; Unni et al., 2004) , we investigated the role of ERK signaling pathway in G q -mediated activation of AR. G q Q209L RGS2 inhibits androgen receptor X Cao et al plasmid was transfected into LNCaP-C33 cells without or with RGS2 or RGS2N149A plasmids and the level of active ERK1/2 (phosphorylated) in cell lysates was determined by Western blot assay using antiphosphorylated ERK1/2 antibody. As shown in Figure 6a (upper panel), transfection of G q Q209L was associated with an induction of ERK1/2 phosphorylation that was blocked by co-transfected RGS2 but not RGS2N149A. As a control, MEK inhibitor U0126 (10 mM) completely diminished G q Q209L-stimulated ERK1/2 phosphorylation. Activated ERKs can phosphorylate transcription factors such as Elk-1, thus ERK activity in LNCaP cells can be estimated through the measurement of ERK-activated, Elk-1-dependent expression of a luciferase reporter gene (Guha et al., 2001) . As shown in Figure 6b , transfection of G q Q209L gene into LNCaP-C33 cells stimulated the Elk-1-dependent luciferase activity by about three-fold. Co-transfection with plasmid expressing the wild-type RGS2 blocked the G q -stimulated, Elk-1-dependent luciferase activity in a dose-dependent manner with at least a 70% inhibition. 
RGS2 inhibits androgen receptor X Cao et al
In contrast, the GAP-deficient RGS2N149A mutant had no inhibitory effect. As a control, the G q Q209L-stimulated, Elk-1-dependent luciferase activity was abolished in LNCaP-C33 cells pretreated with the MEK inhibitor U0126 (10 mM). We also examined the effect of RGS2 on epidermal growth factor (EGF)-induced ERK activity. As shown in Figure 6b (inset), treatment with EGF (25 ng/ml) increased Elk-1-dependent luciferase activity in LNCaP-C33 cells by six-fold, which was not affected by the expression of RGS2. We next assessed the effects of inhibition of endogenous ERK1/2 activity on G q Q209L-induced AR activation using MEK1-K97 M and ERK2-K52R dominant-negative mutants (DN) (Frost et al., 1994) . As shown in Figure 6c , the G q Q209L-stimulated AR-regulated luciferase activity was inhibited over 60% in LNCaP-C33 cells transfected with MEK1/ERK2 (DN). In contrast, expression of these mutants had a minimal effect on the R1881-stimulated AR activity, suggesting that ERK1/2 signaling pathway is responsible for androgen-independent, but not androgen-dependent activation of AR in G q Q209L-transfected LNCaP-C33 cells. This conclusion was further supported by the result that LNCaP-C33 cells treated with the MEK inhibitor U0126 (10 mM) for 30 min prior to transfection had significant lower androgen-independent AR activity but only a slight reduction in androgen-dependent AR activity (Figure 6c ). In addition, the inhibition of G q Q209L-stimulated AR activity by exogenous RGS2 plus MEK1/ERK2 (DN) was only slightly greater than RGS2 or MEK1/ERK2 (DN) alone.
We further investigated whether downregulation of RGS2 expression contributes to constitutively activated ERK activity in LNCaP-C81 cells. As shown in Figure 6a (lower panel), the level of active ERK1/2 (phosphorylated) in LNCaP-C81 cells was significantly higher compared to LNCaP-C33 cells, consistent with the previous reports that ERKs were activated in androgen-independent LNCaP cells in the absence of exogenous androgen (Lee et al., 2003; Unni et al., 2004) . Expression of RGS2 or treatment of MEK inhibitor U0126 strongly decreased the level of active ERK1/2 (phosphorylated) in LNCaP-C81 cells. We then examined the exogenous expression of RGS2 on ERK activities in LNCaP-C81 cells. As shown in Figure 6d , under steroid-reduced medium, ERK-activated, Elk-1-dependent luciferase activity in androgen-independent LNCaP-C81 cells was five-fold higher than that in androgen-sensitive LNCaP-C33 cells. Transfection with plasmid encoding the wild-type RGS2 into LNCaP-C81 cells reduced the Elk-1-dependent luciferase activity in a dose-dependent manner with a maximum inhibition of over 80%. Interestingly, the GAP-deficient mutant RGS2N149A had a modest inhibitory effect (B40%, Po0.01) in LNCaP-C81. This result was supported by the data that RGS2N149A also partially reduced the level of active ERK1/2 in LNCaP-C81 cells (Figure 6a , lower panel). Thus, our results suggest that RGS2 can inhibit ERK activity independently of its GAP activity in LNCaP-C81 cells. This is consistent with the fact that GAP activity is not the only activity ascribed to RGS2 (Kehrl and Sinnarajah, 2002 ) (see Discussion). In contrast, due to low basal ERK activity in LNCaP-C33 cells, neither the wild-type RGS2 nor RGS2N149A had a significant effect. Thus, RGS2 selectively inhibits constitutively activated ERK activity in androgen-independent LNCaP-C81 cells. As a control, Elk-1-dependent luciferase was strongly reduced in LNCaP-C81 and LNCaP-C33 cells pretreated with the MEK inhibitor U0126 (10 mM).
RGS2 modulates androgen-independent growth of LNCaP cells
We next performed colony formation assays to test the growth-inhibitory effect of RGS2. We transfected vectors encoding GFP, GFP-fused RGS2, or GFPfused RGS2N149A mutant into androgen-independent LNCaP-C81 cells, selected the transfected cells with G418 in steroid-reduced medium for 3 weeks, then counted the surviving colonies. In steroid-reduced medium, GFP-fused RGS2 strongly suppressed both the number of colonies by about 70% and size of colonies relative to GFP control (Figure 7a ). GFP-fused RGS2N149A mutant also showed a modest inhibitory effect with a reduction of 40%. These results suggest that in LNCaP cells, RGS2 functions as a potent cell growth inhibitor and the mutation created in RGS2 that disrupts GAP activity only partially limits its ability to inhibit the androgen-independent LNCaP cell growth.
The correlation of hormone refractoriness with downregulated RGS2 expression in androgen-independent prostate cancer cells also prompted us to investigate whether downregulation of RGS2 expression in prostate cancer cells would have a growth advantage under steroid-reduced culture conditions. As shown in Figure 7b , in steroid-reduced medium, androgen-independent LNCaP-C81 cells retained the rapid growth ability, which was independent of androgen R1881 (lane 1 vs 2) but was suppressed about 50% by the expression of exogenous RGS2 (lane 1 vs 3). In contrast, LNCaP-C33 cells grew very slowly in steroid-reduced medium. However, 5 nM R1881 stimulated LNCaP-C33 cell growth by more than six-fold (lane 5 vs 6). Silencing RGS2 in LNCaP-C33 cells by transiently transfected RGS2-specific siRNA (RGS2si-3) enhanced androgenindependent cell growth by about 2.5-fold (lane 5 vs 7) but did not affect R1881-stimulated cell growth (lane 6 vs 8). Thus, downregulation of RGS2 expression facilitates androgen-independent cell proliferation.
Reduction of RGS2 expression in prostate tumors
To further explore the clinical relevance of dysregulation of RGS2 in prostate cancer development and progression, we first used the semiquantitative PCR technique to examine the expression level of RGS2 mRNA in Matched Tumor/Normal prostate tissue RNA pairs (Ambion, Austin, TX, USA). As shown in Figure 8a , the PCR product derived from RGS2 was clearly detected in the normal sample but was decreased by over 70% in the matched tumor whereas expression levels of housekeeping gene b-Actin or cyclophilin B were similar between normal and tumor samples. Since RGS2 and RGS5 are the most related genes in the RGS family (Ross and Wilkie, 2000) , we further examined the expression levels of these two RGS genes in five pairs of prostate tumors and their paired normal tissues using quantitative real-time PCR. The data were shown as the copy number of RGS2 or RGS5 per 1000 copies of b-Actin. All the samples examined showed lower levels of RGS2 mRNA in the tumors as compared to the corresponding normal tissues (Figure 8b ). The mean ratio of amounts of RGS2 mRNA in prostate tumors to those in corresponding normal prostate tissues was 1:6.5 (72.3) (Po0.001, n ¼ 5). When cyclophilin B was used as the normalizing gene, the mean ratio was 1:8 (74) (Po0.001, n ¼ 5) (data not shown). In contrast, no significant difference was observed for the expression level of RGS5 (P>0.05, n ¼ 5).
Discussion
One of major challenges for treating advanced prostate cancer is the acquisition of androgen-independence by prostate cancer cells that causes the failure of hormone ablation therapies. At least a subpopulation of hormone-refractory prostate cancer is thought to be apparently caused by androgen-independent activation of AR. Therefore, a full understanding of the mechanism underlying androgen-independent activation of AR will lead to improved therapies. Recent studies have shown that aberrant GPCR signaling, due to overexpression of GPCRs and/or elevated ligands, can promote androgen-independent prostate cancer cell growth. In the present study, we investigated a possible role of RGS proteins, negative regulators of GPCR signaling, in prostate cancer cells during the transition from an androgen-sensitive to androgen-independent state. Our study presents the first evidence suggesting that the decrease of a RGS protein may play an important role in androgen-independent prostate cancer progression. 
RGS2 inhibits androgen receptor X Cao et al
First, we showed that the expression level of RGS2 is selectively reduced in androgen-independent prostate cancer LNCaP-C81 and CWR22Rv1 cells as compared to androgen-sensitive LNCaP-C33 cells. Conversely, the expression of RGS2, but not other RGS proteins, is able to significantly inhibit androgen-independent, but not androgen-stimulated, AR activity in androgenindependent LNCaP-C81 and CWR22Rv1 cells. These results support the concept that loss of RGS2 expression contributes to the androgen-independent activation of AR in androgen-independent prostate cancer cells.
G proteins are classified into four subfamilies, G s , G i , G q and G 12 (Wilkie et al., 1992) . Since RGS2 inhibits G q -coupled signaling in vivo (Druey et al., 1996; Kammermeier and Ikeda, 1999) , we examined the effect of regulation of G q -signaling by RGS2 on the AR activity using the constitutively activated G q Q209L mutant that mimics the activation of G q signaling pathways by GPCRs. Interestingly, co-expression of wild-type RGS2 but not GAP-deficient RGS2N149A mutant blocked G q Q209L-stimulated AR activity in LNCaP-C33 cells. Since constitutively activated G q Q209L mutant does not hydrolyse its bound GTP even in the presence of RGS proteins (Berman et al., 1996) , the RGS2-mediated inhibitory effect is presumably due to occlusion of the binding site on G q Q209L for its primary effector phospholipase C by RGS2 (Hepler et al., 1997) . This is consistent with the result that G q Q209L can recruit RGS2 to the plasma membrane, which is crucial for the regulation of G protein-coupled signaling by RGS proteins. Thus, our data support the concept that RGS2 inhibits G qmediated stimulation of AR activity through its interaction with G q . This is further supported by the result that RGS2 is unable to suppress RGS-insensitive G q Q209L/G188S-stimulated AR activity in prostate cancer cells, presumably due to loss of interaction between G q Q209L/G188S and RGS2 since G q Q209L/ G188S is unable to recruit RGS2 to plasma membrane.
It should be noted that G q Q209L/G188S has a stronger stimulatory effect on the AR activity than RGS2-sensitive G q Q209L in LNCaP-C33 cells. This result may suggest a possible contribution of endogenous RGS2 in the downregulation of AR activity in LNCaP-C33 cells. Indeed, silencing of endogenous RGS2 in LNCaP-C33 cells by RGS2-specific siRNA activates AR under steroid-reduced medium conditions without any significant effect on androgen-dependent AR activity. Moreover, silencing of endogenous RGS2 further enhances constitutively activated G q Q209L-stimulated AR activity. These results further implicate the involvement of dysregulated RGS2 in the transition of prostate cancer cells from an androgen-sensitive to independent state.
Our data collectively suggest that RGS2 inhibits androgen-independent AR activation by inactivating G q -coupled signaling pathway in prostate cancer cells. Thus, reduced expression of RGS2 can lead to androgenindependent proliferation. However, the mechanism underlying androgen-independent, G q -coupled signalingstimulated AR activity is still unknown. One possible mediator in this pathway is ERK, which has been shown to play an important role in clinical prostate cancer progression (Gioeli et al., 1999; Bakin et al., 2003) . In fact, activation of phospholipase C through G q -coupled receptors, with subsequently increased levels of inositol-1,4,5-trisphosphate, diacylglycerol and free intracellular Ca 2 þ can activate ERK via both Ras-dependent and Ras-independent pathways (reviewed by Gutkind, 2000) . Interestingly, in the presence of U0126, a specific inhibitor of MEK, both ERK activity and AR activity were blocked in LNCaP cells. Since dominant-negative mutants of MEK1 and ERK2 also blocked G q Q209L-stimulated AR activity, our data suggest that ERK1/2 are implicated in the transmission of signal from G q to androgenindependent AR activation in prostate cancer cells. Furthermore, co-expression of RGS2 but not its GAP-deficient mutant inhibited G q Q209L-stimulated ERK activity and AR activity in androgen-sensitive LNCaP-C33 cells under steroid-reduced conditions. In addition, the inhibitory effect by exogenous RGS2 plus dominant-negative mutants of MEK1 and ERK2 was only slightly greater than RGS2 alone, suggesting that RGS2 and dominant-negative mutants of MEK1 and ERK2 block the same G protein-coupled signaling pathway that stimulates the androgen-independent but not androgen-dependent AR activity. In fact, ERKs can directly phosphorylate AR in vitro, and inhibition of ERK activity attenuates the human epidermal receptor 2 (HER2)-mediated activation of AR signaling (Yeh et al., 1999; Lee et al., 2003) . It is possible that RGS2 suppresses androgen-independent AR activity by inhibiting ERK activity in prostate cancer cells. Indeed, the expression of exogenous RGS2 inhibits the constitutively activated ERK activity that only affects androgenindependent AR activity in LNCaP-C81 cells. Our data are consistent with the model depicted in Figure 9 that GPCRs induce androgen-independent AR activation via a signal relay from G q (inactivated by RGS2), MEK1/2 (inhibited by U0126), and ERK1/2 in prostate cancer cells. RGS4, a known GAP toward G i and G q (Hains et al., 2004) , also can inhibit intracellular G q signaling but is less potent compared to RGS2 (Tovey and Willars, 2004) . This is consistent with our observation that at equivalent levels of expression, RGS2 reduced Figure 9 A model for the regulation of androgen-independent AR activation by RGS2 through G q -coupled receptor signaling pathway. Various G protein-coupled receptors (GPCRs) induce androgen-independent AR activation via signaling relay from G q to ERK1/2 in prostate cancer cells. RGS2 inactivates G q , whereas U0126 inhibits MEK1/2. Both inhibit androgen-independent AR activation.
RGS2 inhibits androgen receptor X Cao et al AR-regulated PSA secretion by 90% in LNCaP-C81 cells whereas RGS4 had only a moderate inhibitory effect (about 50%).
Interestingly, the GAP-deficient mutant RGS2N149A also has an inhibitory effect by about 40% on the constitutively activated ERK activity in LNCaP-C81 cells. Such an effect is probably not due to the residual GAP activity of the mutant (o1% of that of the wildtype RGS2). Since RGS2N149A showed no effect on G q -stimulated ERK activity in androgen-sensitive LNCaP-C33 cells, it is likely that signaling pathways other than G q -coupled signaling also contribute to the constitutively activated ERK activity in androgenindependent LNCaP cells, which can be inhibited by GAP-deficient RGS2N149A mutant. In fact, expression of RGS2N149A mutant also showed a partial inhibitory effect on the high basal AR activity in androgenindependent LNCaP-C81 cells (unpublished data). It has been shown recently that G s activates AR in LNCaP cells by stimulating the adenylate cyclase/PKA pathway (Kasbohm et al., 2005) that can activate ERKs via the small G protein Rap1 (Schmitt and Stork, 2000) . Since RGS2 can also directly suppress the adenylate cyclase activity independent of its GAP activity (Sinnarajah et al., 2001; Salim et al., 2003) . It is possible that aberrant activation of the G s /adenylate cyclase/PKA pathway contributes in part to both the constitutively activated ERK activity and high basal androgenindependent AR activity in androgen-independent LNCaP cells, which can be inhibited by the GAPdeficient RGS2N149A mutant. This is further supported by the results that the RGS2N149A mutant could partially inhibit androgen-independent growth of androgen-independent LNCaP-C81 cells. The mechanism underlying the regulation of G s -stimulated AR activity by RGS2 is currently under investigation.
Regulation of the G q -coupled signaling pathway by RGS2 may be physiologically important in the regulation of prostate cancer cell growth. It has been reported that activation of G q -coupled a1-adrenergic receptor by its agonist can stimulate LNCaP cell proliferation in the absence of androgen (Thebault et al., 2003) . Neuropeptides such as neurotensin and bombesin, acting through G q -coupled receptors, also activate AR and enhance the androgen-independent growth of prostate cancer cells (Lee et al., 2001; Dai et al., 2002) . Our data support the notion that RGS2 can inhibit several G q -coupled GPCRs that stimulate the androgen-independent AR signaling pathway, thus attenuating androgen-independent prostate cancer cell growth. Indeed, our colony formation assays demonstrate that RGS2 can inhibit androgen-independent growth of prostate cancer cells. This is further supported by the result that androgensensitive LNCaP cells with silencing RGS2 expression have a growth advantage under steroid-reduced culture conditions, presumably due to the androgen-independent activation of AR. Our findings may have important clinical implications since many patients that become refractory to the hormone therapy still express normal levels of AR-regulated genes (Grossmann et al., 2001) , suggesting that AR is fully functional. Our results therefore predict that prostate cancer cells in which RGS2 is downregulated would be resistant to hormone therapy. In fact, all five prostate cancer specimens tested in our studies have lower levels of RGS2 expression as compared to their noncancerous prostate tissues. Interestingly, a recent study by Hubert Serve's group showed that RGS2 protein was suppressed by fetal liver tyrosine kinase 3 mutants (Flt3-ITD) in the majority of acute myeloid leukemia cases and co-expression of RGS2 with Flt3-ITD inhibited Flt3-ITD-induced autonomous proliferation and clonal growth of myeloid cells (Schwable et al., 2005) . This finding is consistent with our results, suggesting that repression of RGS2 is an important event in the development of different cancers and upregulation of RGS2 can potentially suppress the proliferative signaling in cancer cells. Since expression of RGS2 in androgen-independent prostate cancer cells significantly decreased both the androgen-independent AR activity and cell growth, targeting the RGS2 expression level in prostate cancer cells, in combination with hormone therapy, should significantly improve the treatment of advanced prostate cancer patients.
Early prediction of androgen-independence of prostate cancer is crucial to the treatment of advanced prostate cancer. Since RGS2 expression levels are reduced in androgen-independent prostate cancer cells and in prostate cancer specimens we analysed, the expression levels of RGS2 could potentially be used as a novel marker for predicting the clinical efficacy of antiandrogen therapy. Thus, future studies will be necessary to correlate RGS2 expression levels in clinical prostate cancer samples with tumor progression stages and therapeutic responsiveness to anti-androgen treatment.
Materials and methods

Materials
Ga q , Gb1g2 and m1AchR were purified from Sf9 cells whereas His6 tagged RGS2 protein, wild-type and mutant, were purified from E. coli as described (Tu et al., 2001) . Phenol red-free RPMI-1640 cell media were purchased from Invitrogen. FBS and charcoal-treated certified FBS were from Hyclone (Logan, UT, USA). Rabbit poly-clonal anti-RGS2 C-terminal peptide (KKPQITTEPHAT) antibody was a kind gift from Dr D Siderovski (University of North Carolina at Chapel Hill). The polyclonal rabbit G q antibody (W082-14), a gift from Paul C Sternweis (UT Southwestern Medical Center), was raised against a peptide representing an internal sequence in G q (Gutowski et al., 1991) . Monoclonal mouse anti-human AR antibody, rabbit anti-human PSA antibody, rat anti-HA antibody and rabbit anti-RGS10 antibody were purchased from Santa Cruz. Anti-phosphorylated p44/42 MAP kinases (active ERK1 and 2) antibody (10E) and anti-ERK1/2 total protein antibody were from Cell Signaling Technology. An enhanced chemiluminesence (ECL) reagent kit was purchased from Pierce (Rockford, IL, USA). Nonmetabolizable androgen R1881 was obtained from NEN Life Science Products (Boston, MA, USA). MAPK kinase (MEK) inhibitor U0126 was from Calbiochem. ARE 3 -tk-LUC was a gift from Dr Li-Hua Wang (National Cancer InstituteFrederick Cancer Research and Development Center). It contains three tandem copies of androgen-response element RGS2 inhibits androgen receptor X Cao et al (ARE) from the androgen-responsive, prostate-specific antigen promoter upstream of the tk-LUC reporter. Renilla luciferase expression plasmid, pRL-tk plasmid was a gift from Dr Zhaoyi Wang (Cancer Center, Creighton University). The pFA2-Elk-1 (pGAL4-Elk-1TA) expresses the GAL4 DNA-binding domain fused with the transactivation domain of Elk-1. The reporter plasmid pFR-LUC (pGAL4-LUC) contains 5 copies of the GAL4 binding site upstream of a minimal promoter that drives expression of the firefly luciferase reporter gene. Both were purchased from Stratagene. All pcDNA3.1 plasmids encoding different HA-tagged or un-tagged RGS proteins or constitutively activated G q Q209L were obtained from UMR cDNA Resource Center (Rolla, MO, USA). G q Q209L/G188S was generated from G q Q209L using a QuikChange mutagenesis kit (Stratagene). Gly at position 188 of G q was mutated to Ser using the oligonucleotides 5 0 -GTATTCGATGATCGA TGTGGTGGGGACTC-3 0 and 5 0 -GAGTCCCCACCACAT CGATCATCGAATAC-3 0 . Asn at position 149 of RGS2 was mutated to Ala (N149A) as described previously (Salim et al., 2003) . Green fluorescent protein (GFP)-fused RGS2 or its GAP-deficient N149A mutant was generated by ligating RGS2 or RGS2N149A into pEGFP-N1 (Clontech). Catalytically defective MEK1 mutant (K97M) and ERK2 mutant (K52) were kind gifts from Dr M Cobb (University of Texas Southwestern Medical Center, Dallas, TX, USA). The MEK1-K97M cDNA construct was subcloned into vector pRSET (Invitrogen), and the ERK2-K52R cDNA was subcloned into vector pCMV5M. All plasmids were verified by DNA sequencing. Matched Tumor/Normal prostate tissue RNA pairs were purchased from Ambion (Austin, TX, USA). Prostate tumors and their adjacent normal tissues were obtained from the National Cancer Institute (NCI) Cooperative Prostate Cancer Tissue Resource.
Receptor-G protein vesicles and steady-state GAP assays Unilamellar m1AchR-G q protein vesicles were reconstituted as described previously (Tu et al., 2001) . Steady-state GAP activity was determined according to the increase in agoniststimulated GTPase activity in phospholipid vesicles that contained trimeric G protein and receptor (Wang et al., 1998) .
Cells and cell culture
Low-passage androgen-sensitive LNCaP-C33 (passage o33) was purchased from the American Type Culture Collection (ATCC). They are routinely maintained in RPMI-1640 medium supplemented with 5% FBS at 371C in a humidified atmosphere of 5% CO 2 in air. An androgen-independent high-passage LNCaP-C81 (passage >81) cell line has been established by more than 12-month continuous culture of lowpassage LNCaP-C33 cells as described previously (Igawa et al., 2002) . CWR22Rv1 cells (ATCC, CRL-2505), derived from the relapsed xenograft, were grown in RPMI-1640 medium supplemented with 10% FBS, and 10 mM HEPES.
Transfection and luciferase reporter assays LNCaP cells were transiently transfected using Lipofectaminet 2000 (Invitrogen) in serum-free medium, according to the manufacturer's instructions. Briefly, 0.1 mg of dual luciferase reporter constructs (ARE 3 -tk-LUC and pRL-tk) were cotransfected with pcDNA3.1 empty vector or expression vectors as indicated into 2 Â 10 5 of LNCaP cells in 24-well plates for 16 h followed by incubation in steroid-reduced medium (phenol red-free RMPI 1640 plus 5% charcoal-stripped FBS) with or without R1881 for 24 h. The total amount of plasmid DNA used was normalized to 2 mg/well by the addition of empty plasmid. Renilla luciferase expression plasmid, pRL-tk (10 ng), was used as an internal control for transfection efficiency. Luciferase activities in cell lysates were measured with a Sirius luminometer (Berthold, Germany) using the dual luciferase assay system (Promega) and were normalized by the Renilla activities and protein concentrations of the samples. The results are presented as fold induction, which is the relative luciferase activity (RLUs, ratio of reporter luciferases/Renilla luciferases) of the treated cells over that of the control cells.
Detection of ERK activity
To monitor ERK activities, we used a reporter system (Stratagene) based on the use of fusion proteins that are comprised of a GAL4 DNA binding domain fused to the activation domain of specific transcription factors that, in turn, drive the expression of the luciferase reporter gene (pGAL4-LUC). An expression plasmid (pFA-Elk) expresses a chimeric protein GAL4-Elk1, the phosphorylation target of activated ERKs. Routinely, 2 Â 10 5 of LNCaP cells were co-transfected with pGAL4-LUC (8 ng), pGAL4-Elk-1-TA (8 ng) and either pcDNA3.1 or pcDNA3.1 encoding different genes as indicated (total 2 mg) using Lipofectaminet 2000 (Invitrogen) for 30 h. Luciferase activity was measured using the dual luciferase assay system from Promega.
PSA secretion
LNCaP cells were cultured in phenol-free RPMI 1640 plus 1% charcoal-stripped FBS conditioned medium without or with 5 nM R1881 for 48 h. PSA in 50 ml of collected medium was analysed by Western blotting with the anti-PSA antibody as described below. PSA levels were quantified by densitometry and were corrected for LNCaP cell numbers.
Protein extraction, electrophoresis and Western blot analysis Protein was extracted from exponentially growing cells using 1 Â RIPA complete lysis buffer (Santa Cruz). Protein samples (40 mg) and prestained protein standards were loaded on 10% SDS polyacrylamide gels, electrophoresed and transferred onto a PVDF membrane (Immobilon, pore size 0.45 mm). Immunoblots were probed with antibodies against AR, RGS2, RGS10, G q or anti-HA in a 10% blocking solution and developed according to instructions in the ECL kit (Amersham Biosciences). Anti-b-Actin antibody was used to detect Actin in lysates as loading controls. Cell lysates transfected with different plasmids were also analysed by 10% SDS-PAGE and immunoblotting with a monoclonal antibody specific against the phosphorylated ERK1/2. Total ERK1/2 protein was blotted as a control .
RNA interference experiments
Four RGS2 siRNAs were designed according to different regions of RGS2 gene that are unique to RGS2 using siRNA Wizard software on the website of InvivoGen Inc. One relatively potent siRNA (RGS2si-3, targeting RGS2 sequence: 5 0 -AAAGCCACAAATCACCACAGA-3 0 ) was identified by its ability to knockdown RGS2 expression in androgensensitive LNCaP-C33 cells that expresses endogenous RGS2 protein. RGS2 siRNA (1.5 mg) or its scrambled siRNA was transfected into LNCaP-C33 cells (1 Â 10 6 ) with a Cell Line Nucleofector Kit V (Amaxa), and transfected LNCaP-C33 cells were seeded on six-well plates. After 48 h of incubation at 371C, cells were harvested and subjected to luciferase reporter assays and cell growth analysis. We also designed three other RGS2 siRNAs according to different regions of the 3 0 -untranslated region (3 0 -UTR) of RGS2 gene (GenBank Accession No. NM-002923). The short-hairpin-RNA-encoding complementary single-stranded oligonucleotides, which hybridized to give overhangs compatible with BbsI/BbsI, were synthesized and cloned into the expression vector psiRNAhH1zeo (G2) (Invivogen Inc.) that carries an SV40 promoter and a Zeocin resistant gene as a selection marker. The three siRNA expression vectors (2 mg) were transfected into LNCaP-C33 cells as described above. One of them (RGS2si-5, targeting RGS2 3 0 -UTR sequence: 5 0 -GGAAACATCACT CAG AACTAT-3 0 ) strongly downregulated RGS2 expression in LNCaP-C33 cells. Cells transfected with the RGS2si-5 expression vector were harvested 72 h post-transfection and subjected to luciferase reporter assays and cell growth analysis.
Growth assays
Approximately 1 Â 10 4 transfected cells/well were plated in 12-well tissue culture plates (Becton Dickinson) in steroid-reduced medium for 24 h, and then the medium was replaced with fresh steroid-reduced medium without or with 5 nM R1881 for 4 days. Cells were counted using a Coulter Counter ZM (Coulter Electronics). Results represent an average of two independent experiments performed in triplicates.
Colony formation assay
Androgen-independent LNCaP-C81 cells were transfected with a vector encoding GFP, or a vector encoding GFP-fused RGS2 or RGS2N149A mutant. After 24 h, the cells were replated into 60-mm dishes with 3 Â 10 4 cells/dish and the cells were cultured in steroid-reduced medium plus 500 mg/ml G418 for 3 weeks. The colonies were fixed with formalin, stained with Giemsa, and counted. All assays were carried out in triplicates, and the results are expressed as the number of colonies obtained.
Confocal microscopy GFP-tagged RGS proteins were visualized in live LNCaP cells. Microscopy was performed using a Zeiss LSM 510 confocal microscope equipped with three lasers (Argon, Green HeNe and Red HeNe). Enhanced GFP fluorescence was examined under a fluorescein isothiocyanate filter. For each experimental condition, fluorescence distribution patterns similar to the image shown were observed in the majority (>70%) of cells inspected.
Total RNA isolation and reserve transcription Total RNA was isolated from cells or tissues using Trizol Reagent (Life Technologies), according to the manufacturer's protocol. The quality of the RNA was confirmed by visualization of the integrity of the 18S and 28S RNA bands on agarose gel. The concentration of the total RNA was determined by measuring the absorbance at 260 nm with an ultraviolet spectrophotometer. All the RNA samples used for assay were treated with DNase I (Life Technologies) to remove contaminating genomic DNA prior to experiments. The reverse transcription reaction was performed by incubating a reaction mixture containing 0.5 mg RNA, 100 pmol of random hexamer primer (Applied Biosystems), 50 U of reverse transcriptase (Applied Biosystems), 20 U of RNase inhibitor (Promega), and 1 mM dNTP (Life Technologies) in a total of 20 ml reaction buffer at 42 1C for 50 min, followed by 951C for 5 min. The cDNA samples were then stored at À201C until use.
Conventional PCR and quantitative real-time PCR Primers for each gene were chosen with the assistance of the computer program Primer Express (Applied Biosystems). The primers and probes used for conventional PCR and quantitative real-time PCR of RGS genes are listed in Table 1 . The housekeeping genes b-Actin and cyclophilin B were used as control genes.
The conventional PCR cycling conditions were 1 cycle at 941C for 3 min; 30 cycles of 941C -1 min, 551C -1 min, 721C -1 min, followed by 1 cycle of 721C for 7 min. The PCR products were separated by a 4% agarose gel electrophoresis and stained with ethidium bromide, then photographed under UV light. The predicted size of the PCR product was 238-bp for cyclophilin B, 180-bp for b-Actin and 307-bp for RGS2, and confirmed by DNA sequencing analysis.
All real-time PCR reactions were performed using an ABI Prism 5700 Sequence Detection System (Applied Biosystems). For each PCR run, a master mix was prepared on ice with 1 Â TaqMan buffer, 5 mM MgCl 2, 200 mM dNTP, 300 nM of each primer, 150 nM probe, and 1 U of AmpliTaq Gold DNA Polymerase (Applied Biosystems), and 3 ml of cDNA solution in a total of 30 ml. The thermal cycling conditions were an initial denaturation step at 95 1C for 10 min, followed by 40 cycles at 951C for 15 s and 601C for 1 min.
Human b-Actin plasmid was purchased from ATCC (MGC-10559). Human RGS2, RGS5 or cyclophilin B was constructed into pcDNA3.1 (Invitrogen). All plasmids were prepared by using the Qiagen Spin Mini-Prep Kit. Quantification of plasmid was performed by using UV/visible spectrophotometer (Beckman). The plasmid concentration was converted into copy number; a dilution series of each plasmid from 10 7 to 10 2 were used as DNA standard for real-time PCR. All realtime PCR efficiencies were controlled in the range of 100710%. Standard curves were drawn by plotting the threshold cycle (C T ) against the natural log of the copy number of plasmid molecules. The C T was defined as the cycle at which a statistically significant increase in the magnitude of the signal generated by the PCR reaction was first detected. The equations drawn from the graphs were used to calculate the copy numbers of cDNA molecules present in the unknown samples based on the corresponding C T values.
Statistical analysis
Results are expressed as the mean7s.e. of at least three determinations and statistical comparisons are based on the Student's t-test. A probability (P) value of o0.05 was considered to be significant.
